New drug NT-88 aims to improve heart function in early trial

NCT ID NCT07509801

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called NT-88 (Zuozhu Daxi) in 60 adults with heart failure where the heart's pumping ability is mildly reduced. Participants will receive either standard heart failure drugs or standard drugs plus NT-88. The goal is to check safety and see if NT-88 can improve heart function and symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NT-88 (Zuozhu Daxi)

What this could lead to

If it works, this could point toward a new treatment option for heart failure with mildly reduced ejection fraction.

What could go wrong

This is a very early, small study (60 people) focused on safety and preliminary effects. It may not show clear benefit or lead to a proven therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••